How to Start a MedTech Startup in Israel: A Complete Founder's Guide
Starting a MedTech startup in Israel requires: (1) incorporating a company, (2) defining the regulatory pathway (FDA 510(k), De Novo, or PMA; CE marking under MDR; Israeli Ministry of Health registration), (3) securing clinical data, (4) Helsinki Committee approval for pilots, (5) Seed funding. The Israeli MedTech ecosystem is among the top 5 globally by companies per capita.
Why Israel is one of the world's top MedTech hubs
Israel has the highest density of medical device companies per capita in the world. Over 1,500 active MedTech and digital health companies operate in Israel as of 2026, up from around 1,000 in 2018. The ecosystem benefits from three unique advantages: world-class military R&D talent pool (Unit 81, MAMRAM), universal digitized health records going back 30+ years (unique globally), and a tight cluster of hospitals, universities, and clinical research organizations in a small geography.
For a MedTech founder, Israel offers specific advantages over the US: (a) lower development costs, (b) structured access to Leumit's anonymized clinical data via the WeCcelerate-Leumit partnership, (c) shorter clinical pilot timelines thanks to close ties between hospitals and startups, (d) a regulatory pathway through AMAR (Israeli Ministry of Health) that accepts FDA and CE as supporting evidence for most device classes.
Step 1: Define your regulatory pathway before building anything
The single biggest mistake in MedTech is building product before understanding which regulatory class it falls into. A MedTech startup that picks the wrong class wastes 2+ years of engineering. Before writing a line of code, decide: Are you FDA Class I, II, or III? Does your device need 510(k), De Novo, or PMA? Are you CE Class I, IIa, IIb, or III under MDR?
Class I devices (band-aids, thermometers) typically need only registration. Class II (most imaging, many digital health apps) need 510(k) clearance in the US and a Notified Body assessment in the EU. Class III (implantables, life-sustaining devices) need PMA in the US - a 2-4 year process costing scope tailored. Your business plan and funding needs are ENTIRELY different depending on class.
Step 2: The Helsinki Committee approval (Israel-specific)
Any clinical trial or pilot in Israel requires approval from the local hospital's Helsinki Committee (named after the Declaration of Helsinki). This is an institutional review board (IRB) that evaluates the ethical aspects, patient safety, and scientific merit of the proposed study.
The process takes over a flexible duration for a standard protocol, and involves: (1) submitting a detailed protocol document (50-80 pages), (2) informed consent forms translated to Hebrew, Arabic, and Russian, (3) investigator CVs, (4) device safety data, (5) insurance coverage. WeCcelerate-Leumit Accelerator dramatically shortens this timeline (typically to in adjusted timelines) because our partnership pre-negotiates hospital access and provides templated protocols.
Step 3: Secure clinical data (the biggest bottleneck)
The hardest problem in MedTech is not technology - it's data. Building an AI-based diagnostic tool without access to a labeled, representative dataset is impossible. In the US, startups compete fiercely for hospital partnerships; in Israel, access goes through one of the four HMOs (Leumit, Maccabi, Clalit, Meuhedet) or one of the major hospitals (Sheba, Ichilov, Hadassah).
WeCcelerate's strategic partnership with Leumit Health Services provides structured access to anonymized clinical data and pilot opportunities - subject to Helsinki Committee approval and privacy regulations. For AI/ML-based MedTech, structured data access is often a meaningful differentiator.
Step 4: Funding MedTech in Israel
MedTech startups raise differently than SaaS. Typical progression: (1) Government grants - Israel Innovation Authority (up to 50-85% of R&D costs, non-dilutive). (2) Seed round - scope tailored from specialized MedTech angels and micro-VCs (aMoon, TauVentures, Alpha Capital). (3) Series A - scope tailored from dedicated MedTech funds (OrbiMed, Entrée Capital, Pitango HealthTech). (4) Strategic partnership - late-stage rounds often include corporate VCs from pharma (J&J Innovation, Bayer Life Sciences).
Total capital needed to reach market for a Class II device: scope tailored over a multi-year horizon. For a Class III device: scope tailored+ over a multi-year horizon. Digital health startups (SaaS-like) can reach market for scope tailored in 2-3 years if regulation is minimal (Class I) or absent (pure wellness).
Step 5: The Israeli MedTech network effect
Beyond regulation and funding, Israeli MedTech startups have access to a dense professional network: IATI (Israel Advanced Technology Industries), ILSI-BIOMED (annual MedTech conference), the Israel Innovation Authority's MedTech track, and the Israeli Medical Association. Every major Israeli hospital has a Technology Transfer Office that actively licenses IP to startups.
WeCcelerate-Leumit specifically offers: (1) Former FDA senior advisors on the advisory team, (2) Leumit clinics for clinical pilot opportunities, (3) introductions to a network of MedTech-focused investors in Israel and the US, (4) strategic partnership opportunities with pharma companies, (5) regulatory submission support for FDA 510(k), CE, and AMAR.
Step-by-step
Validate clinical need with 30+ physician interviews
Before any technology work, interview 30+ practicing physicians in your target specialty. Understand the workflow, the pain, and whether your proposed solution fits into the clinical routine.
Classify your device
Determine FDA class (I, II, III) and CE class (I, IIa, IIb, III). This drives every subsequent decision - regulatory pathway, clinical data needs, funding requirements.
Incorporate and build founding team
Israeli incorporation: days to weeks, ~scope tailored. Founding team should include a clinical co-founder (MD) or clinical advisor from day 1.
Secure non-dilutive funding
Apply to Israel Innovation Authority (50-85% of R&D), MAGNET consortia, and Horizon Europe. Non-dilutive funding extends runway significantly in MedTech.
Get Helsinki Committee approval
For any clinical pilot, submit to the hospital's Helsinki Committee. Plan for over a flexible duration (WeCcelerate-Leumit shortens this to in adjusted timelines).
Run a clinical pilot
Start with 20-50 patient pilot to generate safety + efficacy evidence. Use pilot data to support FDA submission and raise Seed funding.
Submit FDA 510(k) or CE
Average FDA 510(k) clearance timeline: over a flexible duration. CE under MDR: over a flexible duration via Notified Body. Budget: scope tailored per regulatory filing.
Apply to WeCcelerate-Leumit
The fastest path to the Israeli MedTech ecosystem.
Frequently Asked Questions
How long does it take to start a MedTech startup in Israel?
How much capital do I need for a MedTech startup in Israel?
What's the Helsinki Committee in Israel?
Can Israeli MedTech use FDA approval for Israeli market?
What is the Israel Innovation Authority grant?
Who are the major MedTech investors in Israel?
What access to medical data does WeCcelerate provide?
Join WeCcelerate-Leumit MedTech Accelerator
The WeCcelerate team has supported ventures launched that collectively significant capital raised. Start with a free introductory call.